

PIXYL raises € 2.2 million to improve patient care by placing the most advanced neuroimaging AI technology in the hands of radiologists and clinicians.

Grenoble, April 29, 2021 - <u>PIXYL</u>, the <u>award-winning</u> French medtech specialized in delivering Al-powered clinical diagnostic support to radiologists and clinicians, announces a € 2.2 million round led by Elaia, and alongside new investors Holnest and Bpifrance. The company is also pleased to welcome an additional 32 radiologists and clinicians as business angels, including Groupe Clinique du Mail.

Pixyl is on a mission to make precision medicine the standard of care. This round will boost the European market launch of Pixyl.Neuro[™], the company's first Al-powered, CE-marked, medical device. The funds will also support FDA regulatory clearance of the company's products for our future U.S. expansion, as well as developing Pixyl's product lines in predictive medicine and differential diagnostics.

"Our investment in Pixyl perfectly illustrates our belief in deep tech to revolutionize healthcare delivery. The Pixyl team has established an extremely solid reputation within the medical community, with a proven track record of bringing high-value Al-based medical devices to market. The impressive client feedback attests to the ability of Pixyl to profoundly transform the radiology workflow, for the benefit of medical professionals, the healthcare system, and ultimately the patient." says Benoit Georis, Investment Director at Elaia.

"Radiology is confronted with several challenges. Among them, workforce reduction and rising demand compels radiologists to work swiftly, without compromising on quality and precision", notes **Dr Stéphane Cantin, neuroradiologist at Groupe Clinique du Mail**. Pixyl helps radiologists and clinicians by automatically analysing brain imaging exams in a matter of minutes, highlighting anomalies, and extracting clinically-relevant measurements for improved insight and decision-making in patient diagnosis and treatment. "Al is the breakthrough that allows us to address these challenges and go further: Pixyl's solution enables reproducible analysis, with disease quantification that is not manually feasible, and ultimately accelerated patient throughput."

Our CE-marked medical device, Pixyl.Neuro[™], supports radiology workflows in modern healthcare facilities by reducing neuroimaging reporting time by 50%¹, while

¹ CHU Clermond-Ferrand

at the same time providing the radiologist and clinician with actionable health information.

Alexandre Aulas, Managing Director at Holnest adds: "For us, Pixyl represents the future of medical imaging and fits perfectly into the natural evolution of healthcare practice. We were particularly impressed, alongside the members of the Holnest Club, by the solution's ability to be integrated into the daily life of the doctors who use it. This funding round will allow Pixyl to keep their technological lead over the competition and democratize the solution at an international level."

According to **Senan Doyle, CEO at Pixyl**, "Precision medicine heralds a new era in patient care. One where medical professionals using the latest AI solutions can instantly access the information needed to diagnose and treat diseases earlier. At Pixyl, we are committed to improving patient outcomes by placing the most advanced AI in routine clinical practice."

About Pixyl

A spin-out of the French labs Inria and Inserm, Pixyl was founded in 2015 by Senan Doyle Ph.D., Prof. Florence Forbes², and Prof. Michel Dojat³, to transform healthcare delivery by allowing treatment to be tailored to individual patients. The company rose to prominence by winning the French Radiology Society data challenge, where Pixyl's AI tech accurately predicted the future clinical disability of multiple sclerosis patients from a single MRI image. Our technology is used by over 40 public and private imaging centres in France, Spain and Italy, with partners that include the French Observatory of Multiple Sclerosis (OFSEP). Pixyl has 15 employees.

About Holnest

Holnest is the Family Office of the Aulas family. Holnest's ambition is to continue and accelerate the entrepreneurial adventure that began over thirty years ago, with the creation of Cegid and the takeover, then development, of Olympique Lyonnais. The objective is to deploy an active strategy in its areas of expertise (Digital, Deeptech, Entertainment, Services, ...) and in all those whose development can be accelerated with digital. Holnest is led and directed by Alexandre Aulas and Patrick Bertrand.

About Elaia

Elaia is a European top-tier VC firm with a strong tech DNA. We back tech disruptors with global ambition from early stage to growth development. For the past 18 years,

² Inria, Statify Team, LJK, UGA

³ Inserm, Grenoble Institute of Neurosciences, UGA

our commitment has been to deliver high performance with values. We are proud to have been an active partner in over 100 startups including success stories such as Criteo (Nasdaq), Orchestra Networks (acquired by Tibco), Teads (acquired by Altice), Mirakl (valued \$1.5B in Series D) and Shift Technology.

Learn more http://www.elaia.com • @Elaia_Partners